Latanoprost Mylan Generics Italia

Latanoprost, the active ingredient in Latanoprost Mylan Generics Italia, is a prostaglandin analog presented as an ophthalmic solution for ocular (topical) use. It lowers intraocular pressure by enhancing aqueous humor outflow and is indicated for the management of elevated intraocular pressure, open‑angle glaucoma, and ocular hypertension in adult patients.

GNH USA supplies Latanoprost Mylan Generics Italia as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality standards.

Latanoprost is a prostaglandin analog used to manage conditions associated with elevated intraocular pressure. - Elevated intraocular pressure: reduces pressure to prevent optic nerve damage. - Open-angle glaucoma: lowers pressure to slow disease progression. - Ocular hypertension: decreases pressure to reduce risk of developing glaucoma.

Latanoprost may cause ocular and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye itching or irritation: transient discomfort. - Increased eyelash growth: longer, thicker lashes. - Darkening of iris pigment: gradual brownish discoloration. - Dry eye sensation: mild dryness.

Serious or Rare Side Effects: - Severe eye inflammation: uveitis or iritis. - Corneal edema: swelling of the cornea. - Vision loss: rapid decrease in visual acuity. - Allergic reaction: swelling, rash, or anaphylaxis.

Before prescribing Latanoprost, clinicians should consider several safety and handling precautions. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown; caution advised. - Pre‑existing ocular inflammation: may worsen condition. - Contact lens wearers: may experience lens discoloration; advise removal. - Concomitant ocular surgery: postpone use until healing. - Store at room temperature: keep bottle in original packaging, protect from light and moisture.

Latanoprost can interact with other ophthalmic agents or systemic drugs that affect intraocular pressure.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory eye drops: may reduce Latanoprost efficacy. - Prostaglandin synthesis inhibitors: antagonize therapeutic effect.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive IOP‑lowering effect, monitor pressure. - Carbonic anhydrase inhibitor eye drops: potential enhanced pressure reduction. - Systemic carbonic anhydrase inhibitors: may increase ocular side effects. - Topical corticosteroids: may counteract pressure‑lowering action.